Journal of Cancer Research and Therapeutics Close
 

Figure 1: Overall survival Kaplan–Meier analysis in patients subjected to ESHAP and GPD regimen. (ESHAP: etoposide, cisplatine-solumedrol, aracytine, GPD: gemcitabine, dexamethasone, cisplatine)

Figure 1: Overall survival Kaplan–Meier analysis in patients subjected to ESHAP and GPD regimen. (ESHAP: etoposide, cisplatine-solumedrol, aracytine, GPD: gemcitabine, dexamethasone, cisplatine)